Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Alpha-1 Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Alpha-1 Proteinase Inhibitors Prior Authorization Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for alpha-1 proteinase inhibitor products for Boeing commercial members, including initial and renewal coverage criteria for alpha-1 antitrypsin deficiency and steroid-refractory acute graft-versus-host disease.

    Policy Summary
    PayerPrime Therapeutics
    PolicyAlpha-1 Proteinase Inhibitors Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for the diagnosis, phenotype, alpha-1 antitrypsin concentration, pulmonary findings, treatment history, specialist involvement, contraindication screening, and requested dose.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6 monthsMaximum aGVHD approval
    12 monthsAATD and renewal approval
    ≤57 mg/dLRequired AAT concentration
    30–65%Baseline FEV1

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8 dosesMaximum prior aGVHD doses

    Coverage Criteria

    Initial Therapy

    Target agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • ONE of the following

      • Alpha-1 antitrypsin deficiency (AATD)

        • The patient has a diagnosis of alpha-1 antitrypsin deficiency (AATD).
        • The patient has PiZZ, PiZ (null), or Pi (null, null) phenotypes.
        • The patient has a low serum concentration of alpha-1 antitrypsin (AAT), measured by nephelometry or ELISA.≤ 57 mg/dL by nephelometry or ≤ 11 micromol/L by ELISA
        • ONE of the following at baseline (prior to therapy with the requested agent)

          • The patient has clinically evident emphysema, as demonstrated by an FEV1 of 30-65% of predicted.FEV1 30-65% predicted
          • ONE of the following demonstrating clinically significant and progressive lung disease

            • Accelerated decline in lung function, such as an FEV1 decline greater than 100 mL/year or a DLCO decline greater than 15% per year.FEV1 decline > 100 mL/year or DLCO decline > 15% per year

              Medical records required.

            • Requirement for supplemental oxygen at rest or with exertion.
        • The patient has evidence of panacinar/panlobular emphysema or centrilobular emphysema.
        • ONE of the following

          • The patient's age is within FDA labeling for the requested indication for the requested agent.
          • There is support for using the requested agent for the patient's age for the requested indication.
      • Acute graft-versus-host disease (aGVHD)

        • The patient has acute graft-versus-host disease (aGVHD).
        • The patient has received a hematopoietic stem cell transplant (HSCT).
        • The patient is 18 years of age or over.
        • The requested agent will be used for steroid-refractory acute GVHD.
        • The patient has not had greater than or equal to 8 doses of the requested agent for the requested indication.< 8 prior doses
        • The requested agent will be used in combination with systemic corticosteroids as additional therapy following no response to first-line therapy options.
    • The patient does not have immunoglobulin-A (IgA) deficiency with antibodies against IgA.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., pulmonologist or transplant specialist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.
    • The patient does not have any FDA-labeled contraindications to the requested agent.
    • The requested quantity (dose) is within FDA labeling or supported in compendia for the requested indication.

      Compendia allowed: AHFS; DrugDex level 1 or 2a evidence; or NCCN level 1 or 2a recommended use.

    Continuation Therapy

    Target agent(s) will be approved when ALL of the following are met:

    ALL of the following

    • The patient has been previously approved for the requested agent through the plan's Prior Authorization process.

      Patients not previously approved for the requested agent require initial evaluation review. Requests for acute graft-versus-host disease (aGVHD) should always be reviewed under Initial Evaluation.

    • The patient has had clinical benefit with the requested agent.
    • The patient does not have immunoglobulin-A (IgA) deficiency with antibodies against IgA.
    • The prescriber is a specialist in the area of the patient's diagnosis (e.g., pulmonologist or transplant specialist), or the prescriber has consulted with a specialist in the area of the patient's diagnosis.

    Acute graft-versus-host disease (aGVHD) coverage is excluded when the patient has received greater than or equal to 8 doses of the requested agent for the requested indication.

    Coverage is excluded for patients with immunoglobulin-A (IgA) deficiency who have antibodies against IgA. Coverage is also excluded when the patient has any FDA-labeled contraindication to the requested agent.

    Clinical Thresholds and Coding Details

    Alpha-1 antitrypsin serum concentration
    Qualifying concentration≤57 mg/dL or ≤11 micromol/L
    Nephelometry measurementThe concentration must be measured by nephelometry when reported in mg/dL.
    ELISA measurementThe concentration must be measured by ELISA when reported in micromol/L.
    Baseline FEV1
    Required rangeFEV1 must be 30–65% of predicted.
    TimingThe measurement must be obtained at baseline, before therapy with the requested agent.
    Qualifying finding

    Provider Actions and Request Guidance

    Prior Authorization

    Initial Prior Authorization Review

    Prior authorization is required for Alpha-1 Proteinase Inhibitors. Initial evaluation applies to requests for alpha-1 antitrypsin deficiency (AATD) or steroid-refractory acute graft-versus-host disease (aGVHD), and approval requires all applicable clinical criteria to be met.

    • AATD requests receive initial review when the patient has qualifying phenotype, low alpha-1 antitrypsin concentration, and qualifying pulmonary disease.
    • aGVHD requests should always be reviewed under Initial Evaluation, including requests for patients not previously approved through the plan's prior authorization process.
    • Length of approval is 12 months for AATD and 6 months for aGVHD.
    Prior Authorization

    Renewal Prior Authorization Review

    Submit renewal requests with documentation supporting continued use and all renewal criteria. Renewal approval is evaluated for a 12-month period.

    • Include the requested agent, diagnosis, current quantity or dose, and relevant clinical documentation with the renewal submission.

    Policy Background

    This policy addresses intravenous alpha-1 proteinase inhibitors for two covered conditions: alpha-1 antitrypsin deficiency with clinically significant pulmonary disease and steroid-refractory acute graft-versus-host disease after hematopoietic stem cell transplant. Alpha-1 antitrypsin deficiency coverage requires a qualifying severe phenotype, a low serum alpha-1 antitrypsin concentration, and evidence of emphysema or progressive lung disease. Acute graft-versus-host disease coverage is limited to adults receiving the agent with systemic corticosteroids after failure of first-line therapy.

    Clinical Definitions

    Alpha-1 antitrypsin deficiency
    Qualifying phenotypesPiZZ, PiZ (null), or Pi (null, null).
    Serum concentrationAlpha-1 antitrypsin concentration must be ≤57 mg/dL by nephelometry or ≤11 micromol/L by ELISA.
    Related pulmonary diseaseCoverage requires clinically significant emphysema or progressive lung disease in addition to the qualifying phenotype and low concentration.
    Steroid-refractory acute graft-versus-host disease
    Post-transplant conditionAcute graft-versus-host disease occurring after hematopoietic stem cell transplant.
    Steroid-refractory statusThe disease must be refractory to steroid therapy.

    Initial Evaluation

    Renewal Evaluation

    Policy Summary
    PayerPrime Therapeutics
    PolicyAlpha-1 Proteinase Inhibitors Prior Authorization Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for the diagnosis, phenotype, alpha-1 antitrypsin concentration, pulmonary findings, treatment history, specialist involvement, contraindication screening, and requested dose.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and Coding DetailsProvider Actions and Request GuidancePolicy BackgroundClinical DefinitionsInitial EvaluationRenewal Evaluation
    The patient does not have any FDA-labeled contraindications to the requested agent.
  1. The requested quantity (dose) is within FDA labeling or supported in compendia for the requested indication.

    Compendia allowed: AHFS; DrugDex level 1 or 2a evidence; or NCCN level 1 or 2a recommended use.

  2. This criterion applies to clinically evident emphysema.
    Accelerated FEV1 decline
    Annual decline thresholdFEV1 decline must be greater than 100 mL per year.
    Clinical contextThe decline must demonstrate clinically significant and progressive lung disease.
    DocumentationMedical records are required to document accelerated decline in lung function.
    DLCO decline
    Annual decline thresholdDLCO decline must be greater than 15% per year.
    Clinical contextThe decline must demonstrate clinically significant and progressive lung disease.
    DocumentationMedical records are required to document progressive lung disease demonstrated by the decline.
    Prior acute GVHD doses
    Permitted prior dosesThe patient must have received fewer than 8 doses of the requested agent for acute graft-versus-host disease.
    Exclusion thresholdInitial requests are not eligible when the patient has received 8 or more doses for that indication.
    Review typeAcute graft-versus-host disease requests are evaluated under initial therapy criteria.
  3. The patient must continue to meet applicable safety, specialist-prescriber, contraindication, and dosing or compendia-support requirements.
  4. Documentation Required

    Progressive Lung Disease Records Required

    For clinically significant and progressive lung disease, submit medical records demonstrating the patient's accelerated decline or need for supplemental oxygen at baseline before therapy with the requested agent.

    • Document accelerated decline in lung function, such as FEV1 decline greater than 100 mL per year or DLCO decline greater than 15% per year.
    • Alternatively, document the requirement for supplemental oxygen at rest or with exertion.
    Documentation Required

    Clinical Assessment and Treatment Documentation

    Include documentation establishing the diagnosis, disease phenotype, laboratory findings, pulmonary status, and treatment history relevant to the requested indication.

    • For AATD, document PiZZ, PiZ (null), or Pi (null, null) phenotype; serum AAT concentration less than or equal to 57 mg/dL by nephelometry or less than or equal to 11 micromol/L by ELISA; and qualifying emphysema or progressive lung disease.
    • Document panacinar or panlobular emphysema or centrilobular emphysema, with clinically evident emphysema demonstrated by FEV1 of 30–65% of predicted when applicable.
    • For aGVHD, document hematopoietic stem cell transplant, age 18 or older, steroid-refractory disease, use with systemic corticosteroids after no response to first-line therapy, and the relevant treatment history.
    • Identify the specialist prescriber or specialist consultation and provide age-related FDA-labeling support or compendia support when applicable. Compendia allowed: AHFS, DrugDex level 1 or 2a evidence, or NCCN level 1 or 2a recommended use.
    Denial Risk

    Failure to Meet Safety or Dosing Criteria

    Requests may be denied when applicable clinical safety or dosing criteria are not met.

    • The patient must not have IgA deficiency with antibodies against IgA.
    • The patient must not have an FDA-labeled contraindication to the requested agent.
    • The requested quantity or dose must be within FDA labeling or supported in compendia for the requested indication.
    Denial Risk

    Excess Prior Doses for Acute GVHD

    For acute GVHD, requests may be denied when the patient has already received 8 or more doses of the requested agent for the requested indication.

    • Document the number of prior doses when submitting an aGVHD request.
    Denial Risk

    No Prior Approval or Clinical Benefit

    Renewal requests may be denied when the patient was not previously approved through the plan's prior authorization process or has not demonstrated clinical benefit with the requested agent.

    • Patients without prior approval require initial evaluation review; aGVHD requests are always reviewed under Initial Evaluation.
    • Submit clinical documentation demonstrating benefit from ongoing treatment.
    Treatment context
    The requested agent is used with systemic corticosteroids as additional therapy after no response to first-line treatment options.